Skip to content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. (HOWL) Q1 2026 Earnings

HOWL·Reported May 7, 2026·Before market open

Diluted EPS came in at $-0.28 (+30.0% YoY), beat the $-0.32 consensus by $0.04.

Diluted EPS
$-0.28beat by $0.04
Consensus: $-0.32
SEC

SEC Filings

Financial Snapshot

Trailing eight quarters through Q1 2026

Q1 2026 Earnings FAQ

Common questions about Werewolf Therapeutics, Inc.'s Q1 2026 earnings report.

Werewolf Therapeutics, Inc. (HOWL) reported Q1 2026 earnings on May 7, 2026 before market open.

Werewolf Therapeutics, Inc. reported diluted EPS of $-0.28 for Q1 2026.

EPS beat the consensus estimate of $-0.32 by $0.04.

Compared to the same quarter a year prior, diluted EPS grew 30.0% from $-0.40.

You can read the 8-K earnings release (0001785530-26-000011) and the 10-Q periodic report (0001785530-26-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.